New Treatment Options for Colorectal Cancer
作者： Charles Erlichman , Daniel J. Sargent
DOI: 10.1056/NEJME048151
关键词:
摘要: Epidermal growth factor receptor (EGFR) is a member of the HER family tyrosine kinase cell-surface receptors that are dysregulated in many types tumor; its expression has been associated with poor prognosis colon cancer.1 There at least two opportunities to interfere EGFR signaling being exploited clinically.2 In one approach, extracellular domain bound by antibodies, such as cetuximab, block ligand-mediated dimerization and subsequent activation receptor. second, drugs inhibit phosphorylation, gefitinib erlotinib. Irinotecan topoisomerase . . .
elsevier.com
sci-hub.se 参考文章(12)
Sufi Mary Thomas, Jennifer Rubin Grandis, Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treatment Reviews. ,vol. 30, pp. 255- 268 ,(2004) , 10.1016/J.CTRV.2003.10.003
J. Randal, Erbitux Trial Flawed From the Beginning, Committee Finds Journal of the National Cancer Institute. ,vol. 94, pp. 1824- 1825 ,(2002) , 10.1093/JNCI/94.24.1824
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Deborah Schrag, The price tag on progress--chemotherapy for colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 317- 319 ,(2004) , 10.1056/NEJMP048143
Daniel J. Hicklin, Lee M. Ellis, Harlan W. Waksal, Andrea T. Hooper, Marie C. Prewett, Rajiv Bassi, Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts Clinical Cancer Research. ,vol. 8, pp. 994- 1003 ,(2002)
V. Grunwald, M. Hidalgo, Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment JNCI Journal of the National Cancer Institute. ,vol. 95, pp. 851- 867 ,(2003) , 10.1093/JNCI/95.12.851
Mace L. Rothenberg, Amit M. Oza, Robert H. Bigelow, Jordan D. Berlin, John L. Marshall, Ramesh K. Ramanathan, Lowell L. Hart, Sunil Gupta, Carlos A. Garay, Brent G. Burger, Nathalie Le Bail, Daniel G. Haller, Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial Journal of Clinical Oncology. ,vol. 21, pp. 2059- 2069 ,(2003) , 10.1200/JCO.2003.11.126
JY Douillard, D Cunningham, AD Roth, M Navarro, RD James, P Karasek, P Jandik, T Iveson, J Carmichael, M Alakl, G Gruia, L Awad, P Rougier, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial The Lancet. ,vol. 355, pp. 1041- 1047 ,(2000) , 10.1016/S0140-6736(00)02034-1
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, Ian Chau, Eric Van Cutsem, None, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 337- 345 ,(2004) , 10.1056/NEJMOA033025
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren, Napoleone Ferrara, Gwen Fyfe, Beth Rogers, Robert Ross, Fairooz Kabbinavar, None, BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER The New England Journal of Medicine. ,vol. 350, pp. 2335- 2342 ,(2004) , 10.1056/NEJMOA032691